ArticleBiomedicines2020
Varespladib Inhibits the Phospholipase A
Article in Biomedicines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 54 citations in OpenAlex.
- Adjunctive Varespladib after antivenom administration for snakebite: A phase II randomized clinical trial.PLoS neglected tropical diseases · 2026Trial
- Rutin (quercetin-3-rutinoside) administered orally after experimental Bothrops jararaca envenomation prevents hemostatic, inflammatory and hemorrhagic disturbances.PLoS neglected tropical diseases · 2026Article
- Nature's antivenom: Combinations of conserved rattlesnake serum metalloproteinase inhibitors block the lethal action of viper venoms.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Role of Regulated Cell Death Pathways in Snakebite Envenomation: Mechanisms, Crosstalk, and Therapeutic Opportunities.International journal of molecular sciences · 2026Review
- Targeting Key Enzymatic Snake Venom Proteins Using Repurposed Small Molecule Inhibitors: Emerging Adjuncts to Antivenom Therapy.International journal of molecular sciences · 2026Review
- Ruthenium Compounds Differentially Inhibit Group IA and IIA Snake Venom Phospholipase AInternational journal of molecular sciences · 2026Article
- Proteomic profiling and comparative hemotoxicity ofThe journal of venomous animals and toxins including tropical diseases · 2026Article
- Secreted Phospholipases A2: Drivers of Inflammation and Cancer.International journal of molecular sciences · 2024Review
- Article
- Dermonecrosis caused by a spitting cobra snakebite results from toxin potentiation and is prevented by the repurposed drug varespladib.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Unraveling snake venom phospholipase APharmacological reports : PR · 2023Review
- Review
- Inhibitory Effects of Varespladib, CP471474, and Their Potential Synergistic Activity onMolecules (Basel, Switzerland) · 2022Article
- Review
- Article
- Alcoholic liver disease: a new insight into the pathogenesis of liver disease.Archives of pharmacal research · 2022Review
- Article
- Analysis of the Composition ofMolecules (Basel, Switzerland) · 2022Article
- Clinical management of snakebite envenoming: Future perspectives.Toxicon: X · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 3 countries.
Funding
Abstract
Phospholipase A
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.